Literature DB >> 26547719

Adverse Drug Reactions Reported to a National HIV & Tuberculosis Health Care Worker Hotline in South Africa: Description and Prospective Follow-Up of Reports.

Christine Njuguna1, Annemie Stewart1, Johannes P Mouton1, Marc Blockman1, Gary Maartens1, Annoesjka Swart1, Briony Chisholm1, Jackie Jones1, Mukesh Dheda2,3, Ehimario U Igumbor4, Karen Cohen5.   

Abstract

INTRODUCTION: The National HIV & Tuberculosis Health Care Worker (HCW) Hotline provides advice on the management of suspected adverse drug reactions (ADRs). We describe suspected ADRs reported to the hotline by HCWs, concordance with advice, and patient outcomes.
METHODS: We reviewed suspected ADRs in HIV-infected patients, patients taking antiretrovirals and patients taking anti-tuberculosis therapy reported from May 2013 to October 2014. We performed causality assessment using the World Health Organization Uppsala Monitoring Centre (WHO-UMC) criteria. We included suspected ADRs categorized as certain, probable or possible in further analysis.
RESULTS: We received 772 ADR reports, of which 87/772 (11.3%) were classified as certain, 176/772 (22.8%) as probable, 361/772 (46.8%) as possible, and 148/772 (19.2%) as unlikely or unassessable. The most frequent ADRs were rash, drug-induced liver injury (DILI) and kidney injury, comprising 110/624 (17.6%), 87/624 (13.9%), and 77/624 (12.3%), respectively. The ADR was severe in 27.3% of rashes, 36.4% of kidney injury reports and 88.5% of DILI reports. Most frequently implicated drugs, either alone or in combination with other potentially causative drugs, were efavirenz (rashes), efavirenz and anti-tuberculosis drugs (DILI) and tenofovir (kidney injury). In 383 cases with HCW follow-up, 254 (66.3%) improved, 9 (2.3%) had complete resolution, 32 (8.4%) remained unchanged, 6 (1.6%) deteriorated, 10 (2.6%) died and 72 (18.8%) had unknown outcome. Advice provided was followed in 93.2% of these cases. Of 223 ADRs with preventability data, 40 (17.9%) were preventable.
CONCLUSION: Queries about rashes, DILIs and kidney injuries were common. Detection and management of these ADRs should be included in HCW training. In cases with follow-up, concordance with advice was high, and HCWs reported improvement in the majority.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26547719      PMCID: PMC4738009          DOI: 10.1007/s40264-015-0359-8

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  16 in total

1.  Focusing on the preventability of adverse drug reactions.

Authors:  G T Schumock; J P Thornton
Journal:  Hosp Pharm       Date:  1992-06

2.  Contribution of the regional drug information center towards drug safety.

Authors:  S Palaian; P Mishra; P R Shankar; D Bista; B Purwar
Journal:  JNMA J Nepal Med Assoc       Date:  2006 Jan-Mar       Impact factor: 0.406

3.  European drug information centres--survey of activities.

Authors:  H Müllerová; J Vlcek
Journal:  Pharm World Sci       Date:  1998-06

4.  Evaluating the uptake, acceptability, and effectiveness of Uliza! clinicians' HIV hotline: a telephone consultation service in Kenya.

Authors:  Charles Karari; Robin Tittle; Jeremy Penner; Jayne Kulzer; Elizabeth A Bukusi; Reson Marima; Craig R Cohen
Journal:  Telemed J E Health       Date:  2011-05-25       Impact factor: 3.536

5.  Utility and value of a medicines information service provided by pharmacists: a survey of health professionals.

Authors:  Joanne E McEntee; Simone L Henderson; Paul M Rutter; Jill Rutter; Helen J Davis
Journal:  Int J Pharm Pract       Date:  2010-12

6.  Impact of the dial access drug information service on patient outcome.

Authors:  P S Melnyk; Y M Shevchuk; A J Remillard
Journal:  Ann Pharmacother       Date:  2000-05       Impact factor: 3.154

7.  Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.

Authors:  Surendra K Sharma; Rohit Singla; Pawan Sarda; Alladi Mohan; Govind Makharia; Arvind Jayaswal; Vishnubhatla Sreenivas; Sarman Singh
Journal:  Clin Infect Dis       Date:  2010-03-15       Impact factor: 9.079

8.  Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey.

Authors:  Johannes P Mouton; Ushma Mehta; Andy G Parrish; Douglas P K Wilson; Annemie Stewart; Christine W Njuguna; Nicole Kramer; Gary Maartens; Marc Blockman; Karen Cohen
Journal:  Br J Clin Pharmacol       Date:  2015-07-06       Impact factor: 4.335

9.  The impact of the National HIV Health Care Worker Hotline on patient care in South Africa.

Authors:  Briony S Chisholm; Karen Cohen; Marc Blockman; Hans-Friedemann Kinkel; Tamara J Kredo; Annoesjka M Swart
Journal:  AIDS Res Ther       Date:  2011-01-26       Impact factor: 2.250

10.  Drug information in Zimbabwe: 1990-1999.

Authors:  Douglas E Ball; Dexter Tagwireyi; Chiedza C Maponga
Journal:  Pharm World Sci       Date:  2007-03-07
View more
  4 in total

1.  Pharmacovigilance: A public health priority for South Africa.

Authors:  Ushma Mehta; Emma Kalk; Andrew Boulle; Portia Nkambule; Joey Gouws; Helen Rees; Karen Cohen
Journal:  S Afr Health Rev       Date:  2017-08-23

Review 2.  Mechanistic insights into antiretroviral drug-induced liver injury.

Authors:  Jamie N Pillaye; Mohlopheni J Marakalala; Nonhlanhla Khumalo; Wendy Spearman; Hlumani Ndlovu
Journal:  Pharmacol Res Perspect       Date:  2020-08

3.  Targeted ultra-deep sequencing of a South African Bantu-speaking cohort to comprehensively map and characterize common and novel variants in 65 pharmacologically-related genes.

Authors:  Sibongile Tshabalala; Ananyo Choudhury; Natasha Beeton-Kempen; Neil Martinson; Michèle Ramsay; Dalu Mancama
Journal:  Pharmacogenet Genomics       Date:  2019-09       Impact factor: 2.089

Review 4.  Management of Antiretroviral Therapy with Boosted Protease Inhibitors-Darunavir/Ritonavir or Darunavir/Cobicistat.

Authors:  Ruxandra-Cristina Marin; Tapan Behl; Nicoleta Negrut; Simona Bungau
Journal:  Biomedicines       Date:  2021-03-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.